Trial
NCT05366855
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Vanda Pharmaceuticals
Collaborators
—
Condition
Generalized Pustular Psoriasis
Intervention
Double-blind 200 mg imsidolimab
Why stopped
AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-27